A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment

You may be eligible if

• Inclusion
• 1. Has provided written informed consent
• 2. Has advanced solid tumors (excluding breast cancer)
• 3. Has normal renal function, mild, moderate, or severe renal impairment and is not on dialysis
• 4. ECOG performance status of ≤2
• 5. Is able to take medications orally
• 6. Has adequate organ function
• 7. Women of childbearing potential must have a negative pregnancy test and must agree to adequate birth control if conception is possible. Males must agree to adequate birth control.
• Exclusion
• 1. Certain serious illnesses or medical condition(s)
• 2. Has had certain other recent treatment e.g. major surgery, anticancer therapy, extended field radiation, received investigational agent, within the specified time frames prior to study drug administration
• 3. Has received TAS-102
• 4. Has unresolved toxicity of greater than or equal to CTCAE Grade 2 attributed to any prior therapies
• 5. Is a pregnant or lactating female